文献速递浆细胞疾病

来那度胺联合地塞米松方案中加用达雷妥尤单抗治疗患者的深度免疫分析

Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab.
PubMed 文献 · Leukemia · 2020-05-26

该研究利用飞行时间流式细胞术,分析了POLLUX三期研究中复发/难治多发性骨髓瘤患者全血样本的免疫细胞变化,比较来那度胺/地塞米松(Rd)与达雷妥尤单抗联合Rd(D-Rd)两组。D-Rd组确认了自然杀伤(NK)细胞减少,残留NK细胞表型改变,CD8+ T细胞优先扩增且与克隆性相关,效应记忆T细胞比例升高,免疫抑制性CD38+调节性T细胞减少。

要点

  • D-Rd组确认了NK细胞减少,残留NK细胞HLA-DR、CD69、CD127和CD27表达增加。
  • D-Rd深度缓解者中T细胞比例优先增加,CD8+ T细胞比例高于CD4+ T细胞。
  • CD8+ T细胞扩增与克隆性相关,D-Rd组效应记忆T细胞比例高于Rd组,CD38+调节性T细胞减少。

核心结论

  • 本研究证实了达雷妥尤单抗联合免疫调节药物时的免疫调节作用机制,并进一步揭示了基于达雷妥尤单抗治疗后免疫细胞变化和活化状态。

研究设计与样本

  • 研究分析了POLLUX三期研究两个治疗组(来那度胺/地塞米松[Rd]或达雷妥尤单抗联合Rd[D-Rd])的复发/难治多发性骨髓瘤患者全血样本,使用飞行时间流式细胞术检测。
  • 基线样本:D-Rd组40例,Rd组45例;治疗2个月后样本:D-Rd组31例,Rd组33例。

主要发现

  • D-Rd组确认了既往报道的NK细胞减少。
  • 残留NK细胞表型不同,HLA-DR、CD69、CD127和CD27表达增加。
  • D-Rd深度缓解者中T细胞比例优先增加,CD8+ T细胞比例高于CD4+ T细胞。
  • CD8+ T细胞扩增与克隆性相关,表明D-Rd产生了适应性免疫应答。
  • D-Rd组效应记忆T细胞比例高于Rd组。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD38-targeted antibody, daratumumab, is approved for the treatment of multiple myeloma (MM). Phase 1/2 studies GEN501/SIRIUS revealed a novel immunomodulatory mechanism of action (MOA) of daratumumab that enhanced the immune response, reducing natural killer (NK) cells without affecting efficacy or safety. We further evaluated daratumumab's effects on immune cells in whole blood samples of relapsed/refractory MM patients from both treatment arms of the phase 3 POLLUX study (lenalidomide/dexamethasone [Rd] or daratumumab plus Rd [D-Rd]) at baseline (D-Rd, 40; Rd, 45) and after 2 months on treatment (D-Rd, 31; Rd, 33) using cytometry by time-of-flight. We confirmed previous reports of NK cell reduction with D-Rd. Persisting NK cells were phenotypically distinct, with increased expression of HLA-DR, CD69, CD127, and CD27. The proportion of T cells increased preferentially in deep responders to D-Rd, with a higher proportion of CD8+ versus CD4+ T cells. The expansion of CD8+ T cells correlated with clonality, indicating generation of adaptive immune response with D-Rd. D-Rd resulted in a higher proportion of effector memory T cells versus Rd. D-Rd reduced immunosuppressive CD38+ regulatory T cells. This study confirms daratumumab's immunomodulatory MOA in combination with immunomodulatory drugs and provides further insight into immune cell changes and activation status following daratumumab-based therapy.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Casneuf T, Adams HC, van de Donk NWCJ, et al. Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia. 2020. PMID: 32457357. doi:10.1038/s41375-020-0855-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。